For younger patients with relapsed or refractory AML, the use of decitabine with venetoclax may be an appropriate salvage therapy, and is comparable to intensive chemotherapy regimens.
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin may benefit patients with treatment-naive or relapsed/refractory acute myeloid leukemia.